Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats

Pharmacology and Toxicology

Volumn 84, Issue 6, 1999, Pages 241-246

  Tada, Hitoshi ^a   Yanagiwara, Seiko ^b   Ito, Kunihiko ^a   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CORTEX; KIDNEY MASS; KIDNEY MEDULLA; MALE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 0033015136     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb01489.x     Document Type: Article

References (19)

1. Alessiani, M., U. Cillo, J. J. Fung, W. Irish, K. Abu-Elmagd, A. Jain, S. Takaya, D. Van Thiel & T. E. Starzl: Adverse effects of FK-506 overdosage after liver transplantation. Transplant. Proc. 1993, 25, 628-634.
2. Brockmoller, J., H.-H. Neumayer, W. Wagner, G. Heinemeyer, H. Kewitz & I. Roots: Pharmacokinetic interaction between cyclosporin and diltiazem. Eur. J. Clin. Pharmacol. 1990, 38, 237-242.
3. Carrier, M., F. Tronc, D. Stewart, S. Nattel & L. C. Pelletier: Blockade of cyclosporine-induced vasocontriction by the calcium channel blocker diltiazem in dogs. J. Thoracic. Cardio. Surg. 1993, 106, 487-490.
4. Dieperink, H., P. P. Leyssac, H. Stakklint, K. A. Jorgensen & E. Kemp: Antagonist capacities of nifedipine, captopril, phenoxybenzamine, prostaglandin and indomethacin on cyclosporin A induced impairment of rat renal function. Eur. J. Clin Invest. 1986, 16, 540-548.
5. Ford J. M. & W. N. Hait: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990, 42, 155-199.
6. Iwasaki, K., H. Matsuda & K. Nagase: Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res. Commun. Chem. Pathol. Pharmacol. 1993, 82, 209-216.
7. Iwasaki, K., T. Shiraga, K. Nagase, K. Hirano, K. Nozaki & K. Noda: Pharmacokinetic study of FK506 in the rat. Transplant. Proc. 1991, 23, 2757-2759.
8. Japanese FK-506 Study Group: Morphological characteristics of renal allografts showing renal dysfunction under FK-506 therapy: Is graft biopsy available to reveal the morphological findings corresponding with FK-506 nephropathy? Transplant. Proc. 1993, 25, 624-627.
9. Kumano, K., G. Wang, T. Endo & S. Kuwano: FK 506-induced nephrotoxicity in rats. Transplant. Proc. 1991, 23, 512-515.
10. Lowry, O. H., N. J. Rosebrough, A. L. Farr & R. J. Randall: Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
11. Morales, J. M., A. Andres, C. Alvarez, C. Prieto, B. Ortuno, T. Ortuno, E. R. Paternina, P. G. Hernandez, M. Praga, L. M. Ruilope & J. L. Rodicio: Calcium channel blockers and early cyctosporine nephrotoxicity after renal transplantation: A prospective randomized study. Transplant. Proc. 1990, 22, 1733-1735.
12. Nakamura, S., T. Suzuki, Y. Sugawara, S. Usaki, Y. Ito, T. Kuma, M. Yoshikawa, H. Endo, M. Ohashi & S. Harigaya: Metabolic fate of diltiazem, distribution, excretion and protein binding in rat and dog. Arzneimittelforsch. 1987, 37, 1244-1252.
13. Pochet, J. M. & Y. Pirson: Cyclosporin-diltiazem interaction. Lancet 1986, 1, 979.
14. Regazzi, M. B., I. Iacona, M. Alessiani, M. Spada, S. Vaccarisi, P. Villani & M. Molinara: Interaction between FK506 and diltiazem in an animal model. Transplant. Proc. 1996, 28, 1017-1018.
15. Schinkel, A. H., E. Wagenaar, L. Van Deemter, C. A. A. M. Mol & P. Borst: Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, cyclosporin A. J. Clin. Invest. 1995, 96, 1698-1705.
16. Shaikh, M. G., S. D. Heys, P. A. J. Brown & P. H. Whiting: Chronic cyclosporin A (CsA) nephrotoxicity in the rat: the effect of calcium blockade with verapamil. Int. J. Exp. Path. 1993, 74, 389-396.
17. Takada K., H. Usuda, M. Oh-hashi, H. Yoshikawa, S. Muranishi & H. Tanaka: Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administration to rats. J. Pharmacobio-Dyn. 1991, 14, 34-42.
18. US Multicenter FK-506 Liver Study Group (Klintmalm, G. B. G., R. Goldstein, T. Gonwa, R. H. Wiesner, R. A. F. Krom, B. W. Shaw, J. R. Stratta, N. L. Ascher, J. W. Roberts, J. Lake, R. W. Busuttil, S. McDiarmid, C. O. Esquivel, P. Nakazato, J. W. Marsh, E. S. Woodle, M. Kalayoglu, A. M. D'Alessandro, J. D. Pirsch, C. Miller, M. Schwartz, W. D. Lewis, A. P. Monaco, R. L. Jenkins, J. C. Emond, J. R. Thistlethwaite, P. F. Whitington, D. R. Steinmuller, W. E. Fitzsimmons & I. Lawrence): Use of Prograf (FK-506) as rescue therapy for refractory rejection after liver transplantation. Transplant. Proc. 1993, 25, 679-688.
19. Woodle, E. S., G. A. Perdrizet, S. So, M. D. Jendrisak, H. M. White & J. W. Marsh FK-506 rescue therapy: Early conversion improves efficacy. Transplant. Proc. 1993, 25, 1990-1991.